Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street

KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice

The NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).

Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More

KaloBios Pharma (KBIO) Continues Run-Up on Epic Short Squeeze

KaloBios Pharma (NASDAQ: KBIO) is continuing higher pre-open Monday as the epic short... More

Macrocure (MCUR) Ramps Higher

Macrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.

KaloBios Pharma (KBIO) Names Martin Shkreli as CEO

KaloBios Pharma (NASDAQ: KBIO) announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David... More

Marek Biestek Bought 200K Shares of KaloBios Pharma (KBIO)

More insider buying was just disclosed on KaloBios Pharma (NASDAQ: KBIO). Marek Biestek bought 200,000 shares from 11/16-11/17 at $1.36-$1.83.

Marek Biestek is a member of a "group" - likely the Martin Shkreli group.

Pre-Open Stock Movers 11/19: (KBIO) (NLST) (STEM) (GMCR) Higher; (SMTC) (TWI) (AMAG) Lower (more...)

KaloBios Pharma (NASDAQ: KBIO) 625% HIGHER; Martin Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.

Netlist, Inc. (NASDAQ: NLST) 65% HIGHER; today announced that it has entered into a five year Joint Development and License Agreement with Samsung Electronics Co., Ltd., to produce a new class of NVDIMM-P (NV-P) memory solutions based on Samsung's industry leading NAND Flash and DRAM, and Netlist's... More

KaloBios Pharma (KBIO) In Discussions with Shkreli Group About Continuing Operations

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding... More

After-Hours Movers 11/18: (KBIO) (VTAE) (GMCR) Higher; (SUNE) (GLBL) (VSLR) Lower (more...)

KaloBios Pharma (NASDAQ: KBIO) 611% HIGHER; Martin Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.

Vitae Pharmaceuticals (NASDAQ: VTAE) 38.7% HIGHER; reported positive top-line results from the healthy human volunteer part of the multiple ascending dose Phase 1 clinical trial of VTP-43742. VTP-43742 is Vitae's wholly owned, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the... More

Anthion Partners II Buys ~700K Shares of KaloBios Pharma (KBIO), Adding to Madness

In addition to the Martin Shkreli buys on KaloBios Pharma (NASDAQ: KBIO) disclosed after the close, Anthion Partners II disclosed it bought 713,726 shares on 11/16 at $1.26-$1.76. Shares are up 700% after-hours.

Market Wrap: Fed Hints at Dec. Hike; China Trims Treasury Holdings; Housing Starts Lags in Oct.; Apple Gains on Goldman Call

Market wrap for November 18th

End of the Day: S&P 500 up 33.1 to 2,083.58; Dow Jones up 247.7 to 17,737.16; Nasdaq up 89.2 to 5,075.20

Market Brief: China lowered its U.S. Treasury holdings to $1.258 trillion, which was the lowest level seen in seven months, while Japan cut its stake to $1.17 trillion, the lowest in nearly two years.

The FOMC indicated that a rate hike might be coming in December, according to the minutes from its latest meeting.

Apple moved higher following... More

Celladon (CLDN) Moves Higher in Concert with KaloBios Pharma (KBIO) Following Shkreli Stake

Celladon (Nasdaq: CLDN) shares are ticking higher in sympathy with KaloBios Pharma (Nasdaq: KBIO).

After markets closed, Martin Shkreli disclosed taking a massive stake in KaloBios. For more color, click here.

Earlier this year, Celladon announced plans to explore alternatives. The stock is up over 20 percent late Wednesday.

With Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4

The upside being seen in KaloBios Pharma (NASDAQ: KBIO) after the close (400%+) after Martin Shkreli... More

KaloBios Pharma (KBIO) Pops on Shkreli Insider Buy

KaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.

Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.

On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner... More